The development of multispecific antibody has become a key technology because it allows multiple targeting, reduces toxicity, and brings immune effector cells into close proximity with cancer cells, ultimately enhancing therapeutic efficacy and preventing drug resistance. Creative Biolabs provides a full range of services of multispecific and multifunctional immune checkpoint antibody development for our clients.
Tumor cells avoid the immune response by exploiting immune checkpoints through the expression of immunosuppressive molecules, recruitment of suppressive immune cell populations, and secretion of soluble suppressive factors. Immune checkpoints are inhibitory pathways integral to the immune system and critical for modulating the immune response to maintain self-tolerance and prevent autoimmunity. Currently, multispecific and multifunctional receptor-targeting antibodies which target immune checkpoints and tumor cells' microenvironment to exert immune modulation function are regarded as an exciting avenue for next-generation cancer therapy.
Fig.1 Multifunctional antibodies targeted tumor and tumor microenvironment. (Zhu, 2015)
The variety and versatility of the available multi-targeting formats provide many opportunities for enhancing antibody-based cancer therapy via the engagement of numerous cell-surface receptors. In some cancer contexts, using a single drug for simultaneous targeting of cell-surface receptors could be superior in terms of dosage, efficacy, and binding affinity compared with monospecific antibodies. At present, many multispecific antibodies targeting immune checkpoints are studied in the preclinical and clinical with cancer. These structurally related targets are of interest because of their overexpression or overactivation in various solid cancer types and their crosstalk capacity, which might have a crucial role in their acquired resistance to monospecific antagonistic antibody therapy.
Many antibody-based therapeutic strategies have been developed to target stromal cells in the tumor microenvironment to enhance anti-tumor immune responses. In particular, blocking immune inhibitory receptors on immune cells allows tumor cells to be subjected to attack from cytotoxic T cells. Recently, bispecific or even multispecific antibodies have been developed that simultaneously target cell-surface receptors on tumor cells and those on immune cells in the tumor microenvironment, such as CD28 and CD3. A range of bispecific antibodies aimed at linking tumor cells and immune cells are currently undergoing clinical trials.
Creative Biolabs is experienced in the design and production of various kinds of multispecific and multifunctional immune checkpoint antibodies. The top research team of Creative Biolabs can make sure to put the necessary resources and solutions to provide customized, high-quality multispecific, and multifunctional antibody development services for our customers worldwide. If you are interested in our services, please contact us for more detailed information.
All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic, or any in vivo human use.